Revolo Biotherapeutics Receives MHRA Approval for Two Phase

Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

Related Keywords

United States , United Kingdom , London , City Of , Jonathan Rigby , Revolo Biotherapeutic , Revolo Biotherapeutics , Revolo Bio , Regulatory Agency , Two Phase , Autoimmune Diseases , United Kingdomi February , Rheumatoid Arthritis , Posterior Uveitis , Eosinophilic Esophagitis , Chief Executive Officer , Vaccine , Immunotherapy , Immune Therapy , Desensitization , Personalized Immunotherapy , Ntigen , Ellular , Recombinant , Protein , Peptide , Subunit , Multivalent , Cancer Vaccine ,